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Abstract: Multiple myeloma (MM) is still considered an incurable hematologic cancer and, in the last
decades, the treatment goal has been to obtain a long-lasting disease control. However, the recent
availability of new effective drugs has led to unprecedented high-quality responses and prolonged
progression-free survival and overall survival. The improvement of response rates has prompted the
development of new, very sensitive methods to measure residual disease, even when monoclonal
components become undetectable in patients’ serum and urine. Several scientific efforts have been
made to develop reliable and validated techniques to measure minimal residual disease (MRD),
both within and outside the bone marrow. With the newest multidrug combinations, a good
proportion of MM patients can achieve MRD negativity. Long-lasting MRD negativity may prove to
be a marker of “operational cure”, although the follow-up of the currently ongoing studies is still
too short to draw conclusions. In this article, we focus on results obtained with new-generation
multidrug combinations in the treatment of high-risk smoldering MM and newly diagnosed MM,
including the potential role of MRD and MRD-driven treatment strategies in clinical trials, in order to
optimize and individualize treatment.
Keywords: multiple myeloma (MM); newly diagnosed; smoldering; minimal residual disease (MRD);
high risk; autologous stem-cell transplantation (ASCT)
1. Introduction
Multiple Myeloma (MM) is a hematologic malignancy caused by the outgrowth of monoclonal
plasma cells that leads to end-organ damage [1]. In 2018, MM accounted for 1.2% of all cancer
diagnoses and 1.6% of all cancer deaths in Europe [2]. The median overall survival (OS) of newly
diagnosed (ND) MM patients improved from 3.9 years for patients diagnosed between 2004 and 2007
to 6.3 years for those diagnosed between 2008 and 2012 to a median OS that is not yet reached in
patients diagnosed after 2012 [3]. The introduction of new drug classes like proteasome inhibitors
(PIs), immunomodulatory drugs (IMiDs), and, more recently, monoclonal antibodies (mAbs) has
been the main determinant of the observed OS improvement, together with an improved supportive
care. Nevertheless, the main cause of death in MM patients is still the development of drug-resistant
disease [4]. Although obtaining deep responses is a universally recognized predictive factor of good
outcome [5], long-term disease control, rather than disease eradication, is still the aim of MM treatment
in current clinical practice, since the available data show that even patients achieving minimal residual
disease (MRD) negativity relapse. This confirms the so-far incurable nature of MM. Recent data,
comparing the survival of young MM patients treated between 2005 and 2015 to that of young patients
affected by curable hematologic diseases (e.g., diffuse large B cell lymphoma (DLBCL) and Hodgkin
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Lymphoma (HL)) [6] and to that of the general population showed that MM patients have a 20-fold
excess mortality compared to the general population, while DLBCL and HL have a non-significant
excess mortality [6].
However, more recent results from clinical trials exploring novel three-drug and four-drug
combinations showed unprecedented rates of prolonged and deep responses [7–11], with acceptable
safety profiles even in elderly patients, thus increasing the likelihood not only to achieve disease
control, but potentially cure, at least in a subset of patients. To design a potentially curative strategy,
we have to focus on the first stages of the disease (smoldering MM (SMM), newly diagnosed MM
(NDMM)), when the patient is treatment-naïve and disease genomic complexity is lower, as compared
to the advanced relapsed/refractory setting.
In this review, we provide a summary of the new techniques used to detect residual disease at
high sensitivity and of the results obtained in SMM and NDMM with new-generation combinations.
We also explore how we can exploit these data in the future, towards a potential cure of MM.
2. Evolution of Response Criteria and MRD Techniques
To enable disease eradication strategies, it is mandatory to have sensitive methods to detect small
amounts of residual disease after treatment. MM response criteria evolved together with therapies.
While before the introduction of novel agents, the rates of complete remission (CR) were very low (2%
after 3 cycles of vincristine–doxorubicin–dexamethasone [12]), with novel combinations CR can now
be obtained in >60% of patients [9]. Conventionally, MM response is evaluated measuring M-protein
levels in the blood and urine, but it is now clear that even when M-protein disappears, residual disease
can still be present [13]. The Spanish group showed that, among patients with a conventionally defined
CR, there was a significant difference in outcome between MRD-negative and MRD-positive patients
(median progression-free survival (PFS) 63 vs. 27 months, p < 0.001; median OS not reached vs.
59 months, p < 0.001). Interestingly, the outcome of patients with MRD-positive CR was similar to
the outcome of those achieving only a partial response (PR), thus suggesting that the advantage of
reaching CR over PR relies on the MRD-negative status. Recently, response criteria have been updated,
introducing a universal definition of MRD beyond CR (for a detailed definition of the updated response
criteria, please refer to Kumar et al., 2016) [14–17].
Two techniques have been developed and validated to detect MRD into the bone marrow:
multiparameter flow cytometry (MFC) and next-generation sequencing (NGS).
MFC detects and quantifies tumor plasma cells using cell surface and cytoplasmic markers.
Neoplastic plasma cells are characterized by the aberrant expression of molecules like CD19,
CD20, CD27, CD28, CD33, CD38, CD45, CD56, CD117, and surface membrane immunoglobulin [18].
The first attempts to detect MRD by MFC had a maximum sensitivity of 10−4–10−5. The optimization
of the MFC assay using two 8-color tubes, a bulk-lysis procedure, the acquisition of ≥107 cells/sample,
and the automatic plasma cell gating through a software tool led to reproducible results and
enhanced the maximum sensitivity to 10−5–10−6 (next-generation flow, NGF) [19,20]. Using NGF,
Flores-Montero and colleagues demonstrated that 25% of patients who were classified as MRD-negative
by second-generation MFC were indeed MRD-positive by NGF [20]. Moreover, NGF negativity
predicted a significantly longer PFS than second-generation MFC negativity among CR patients
(p = 0.02) [20].
NGS technique was mainly developed by Adaptive Biotechnologies (Seattle, WA, USA) by
producing and validating ClonoSEQ®Assay, which has recently obtained, by the Food and Drug
Administration (FDA), the authorization as standardized technique for the disease evaluation in
MM patients [21]. In this test, DNA from the immunoglobulin genes is amplified and sequenced
using baseline bone marrow sample and identical sequences detected in more than 5% of the reads
are identified as clonal gene rearrangements. These rearrangements are then searched in follow-up
samples to identify MRD [22,23]. NGS reaches maximum sensitivity up to 10−6 [21].
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Ongoing clinical trials are evaluating NGS vs. NGF/MFC and their correlation [24], and will
help understand if the two techniques can be considered equivalent in identifying MRD negativity at
a specific cut-off. Each technique has its own advantages and drawbacks (Table 1).
Table 1. Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for the
detection of minimal residual disease (MRD) in multiple myeloma.
Characteristics NGS NGF
Applicability ≥90% ~100%
Baseline sample Required for molecular markeridentification Not required
Number of cells 1–2 million cells/20 µg DNA 10 million cells/tube
Standardization Commercial companies(e.g., Adaptive Biotechnologies) Euro Flow consortium
Sample processing Fresh and/or stored samples Fresh sample required; processingwithin ≤48 h
Sample quality control Not feasible Possible to check by global bonemarrow cell analysis
Quantitative Yes Yes
Sensitivity 1 in 10−5–10−6 1 in 10−5–10−6
Clonal evolution Evaluable Not evaluable
Time required 1 week 3–4 h
Support required Bioinformatics support Expert flow cytometrist;Automated software
MRD, minimal residual disease; NGS, next-generation sequencing; NGF, next-generation flow.
The maximum sensitivity reached is a key point, especially in a curative perspective. Each log
depletion in MRD levels predicts a 1-year median OS advantage (5.9 years at 10−2–10−3, 6.8 years at
10−3–10−4, and ≥7.5 years at 10−4), suggesting that MRD levels at the highest sensitivity should be
pursued [25]. Several reports suggested that once MRD-negative statuses are reached with a high
sensitivity technique, patient prognoses are similar independently from the treatment that induced
MRD negativity [26,27]. This observation also seems to apply to patients with adverse baseline
prognostic factors (e.g., high-risk cytogenetics or elevated Revised International Staging System (R-ISS)
stage), among whom MRD-negative patients at a sensitivity of 10−5–10−6 [26,28], but not at a sensitivity
of 10−4 [29], showed similar clinical outcomes compared to standard-risk patients. Nevertheless,
reaching MRD negativity in high-risk patients may be harder [30], and intensive regimens are likely
needed in this patient population [8,9].
Even when evaluating MRD at a sensitivity of 10−6, there are still patients that can relapse. Relapses
can also be caused by extramedullary disease [31]. Fluorodeoxyglucose (FDG) positron emission
tomography/computed tomography (PET/CT) is currently considered the standard of care to assess
residual disease outside the bone marrow [32,33]. The predictive role of post-treatment PET/CT has been
demonstrated by different studies [34–36] and, in a head-to-head comparison [34], the normalization
of PET/CT outperformed that of conventional magnetic resonance imaging after therapy for the
prediction of PFS and OS. Recently, Zamagni et al. presented data on the standardization of PET/CT to
define criteria for MRD negativity using the 5-point Deauville score. PET/CT imaging was a reliable
predictor of outcomes regardless of treatment. The achievement of a Deauville score ≤3 was the
predictor of a longer time to disease progression and overall survival (OS) and, consequently, a potential
standardized definition of PET/CT negativity [37].
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MRD assessed by PET/CT and bone marrow techniques synergistically predict patient outcome,
with the best PFS detected in patients who were MRD-negative both within and outside the bone
marrow [38]; hence the definition of Imaging MRD negativity.
Both the NGS and the NGF-plus-Imaging approaches are needed for the response evaluation in
the setting of a curative strategy. Nevertheless, from a practical perspective, it should be determined if
all these techniques are necessary for all patients, or if it is possible to develop an algorithm to define
how to proceed. To do this, we need to answer open questions such as: In which patients should we
perform MRD (CR, stringent CR (sCR) very good partial response (VGPR))? What is the proportion
of patients who are still PET-positive despite being MRD-negative in the bone marrow with a high
cut-off level (e.g., 10−6)? Vice versa, how many PET-positive patients are MRD-negative? Who are the
patients that show discrepancies between the two evaluations? Ongoing studies including both BM
and PET/CT evaluation at specific time points will help in drawing conclusions [37].
In the future, liquid biopsy approaches that use peripheral blood samples could potentially
overcome the need to assess MRD both in the bone marrow and by imaging. However, these techniques
are still at early developmental stages [39].
Besides achieving MRD negativity, a more important factor is maintaining it [40]: here comes
the definition of “sustained MRD negativity” by the International Myeloma Working Group (IMWG),
which uses the 1-year cut-off. An effort should be made to define the optimal duration of MRD
negativity to reach an “operational cure”; this still remains an unanswered question, with a potentially
great clinical relevance. For instance, in the chronic myeloid leukemia field, a sustained major molecular
response lasting at least 2 years is usually required to be a candidate for treatment discontinuation [41],
and longer deep molecular response durations prior to discontinuation are associated with the
increasing probability of maintaining a major molecular response after discontinuation [42]. Little data
are available in MM. Using MFC to monitor MM patients after induction and at different time points
post-autologous stem-cell transplantation (ASCT), Gu and colleagues showed that, among patients
achieving MRD negativity after the post-induction time point, MRD reappearance can happen
18–24 months after ASCT, thus suggesting that long-term confirmation of sustained MRD negativity
may be necessary [43].
3. Treatment of High-Risk SMM
SMM [44] is an asymptomatic plasma cell neoplasm harboring a variable risk of progression
to MM. Several scores have been proposed to assess SMM risk of progression to symptomatic MM
(Table 2) [45,46].
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Table 2. Smoldering multiple myeloma: risk stratification systems.
Stratification
System
N
Low Risk Intermediate Risk High Risk
Criteria TTP(Median) Criteria TTP (Median) Criteria
TTP
(Median)
Mayo Clinic
[47] 273
- M-protein <3
g/dL
plus
- BMPCs <10%
19 years
- M-protein <3 g/dL
plus
- BMPCs ≥10%
8 years
- M-protein ≥3
g/dL
plus
- BMPCs ≥10%
2 years
PETHEMA
[48] 89
- Aberrant PCs by
MFC <95%
- Immunoparesis
NR
- Aberrant PCs by MFC ≥95%
OR
- Immunoparesis
6 years
- Aberrant PCs by
MFC ≥95%
AND
- Immunoparesis
1.9 years
Mayo
2/20/20 [45] 421
None of the risk
factors:
- M-protein >2g/dL
- BMPCs >20%
- FLCr >20
9.1 years
One risk factor:
- M-protein >2g/dL
- BMPCs >20%
- FLCr >20
5.6 years
≥2 risk factors:
- M-protein >2g/dL
- BMPCs >20%
- FLCr >20
2.4 years
Low Risk Intermediate Low Intermediate High High Risk
N Criteria
2-year
progression
risk
Criteria
2-year
progression
risk
Criteria
2-year
progression
risk
Criteria
2-year
progression
risk
2/20/20 + CA
by FISH *
[49]
2004
None of the risk
factors:
- M-protein >2g/dL
- FLCr >20
- BMPCs >20%
Presence of any of
the CA *
8%
1 risk factor:
- M-protein
>2g/dL
- FLCr >20
- BMPCs
>20%
Presence of
any of the CA
*
21%
2 risk factors:
- M-protein
>2g/dL
- FLCr >20
- BMPCs
>20%
Presence of
any of the CA
*
37%
≥3 risk factors:
- M-protein >2g/dL
- FLCr >20
- BMPCs >20%
Presence of any of
the CA *
59%
* High-risk chromosomal abnormalities: t(4,14), t(14,16), 1q gain, or del13. N, number; M-protein, myeloma protein; BMPCs, bone marrow plasma cells; CA, chromosomal abnormalities;
FLCr, free light chain ratio; MFC, multiparameter flow cytometry; NR, not reached; PCs, plasma cells; TTP, time to progression; FISH, fluorescence in situ hybridization.
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The 2/20/20 model was the most recently proposed; its name comes from the resulting cut-offs
of M-protein, bone marrow plasma cells (BMPC), and free light chains (FLC). M-protein >2g/dL
(hazard ratio (HR) 1.56, p = 0.01; BMPC % >20% (HR 2.28, p < 0.0001), and FLC ratio (FLCr) >20
(HR 2.13, p < 0.0001)) independently predicted shorter time to progression (TTP) in multivariate
analysis. Three risk groups were identified: Low risk (none of the risk factors), intermediate risk (1
risk factor), and high risk (≥2 risk factors), with a median TTP of 110, 68, and 29 months, respectively
(p < 0.0001) [45]. The high-risk group consisted of 36% of the analyzed cohort of SMM.
A retrospective multicenter study by the IMWG validated the 2/20/20 model; furthermore,
incorporating the cytogenetic abnormalities detected by fluorescence in situ hybridization (FISH;
presence vs. absence of t(4,14), t(14,16), 1q gain, and/or del13), they identified four risk categories
with a 2-year progression risk of 3.7% (low risk), 25% (low–intermediate), 49% (intermediate–high),
and 72% (high) [49].
The current standard of care for SMM is periodical monitoring, with a suggested frequency based
on patient risk to identify the possible evolution to symptomatic MM in due time and avoid severe
organ damage. While this strategy suits well low-risk SMM patients who are unlikely to progress
to MM, it may be questionable in high-risk SMM. In this setting, open questions are: (1) Can these
patients benefit from an early therapy aiming at delaying the very likely evolution to MM? (2) Is there
a possibility that early treatment may actually cure the disease? The latter hypothesis is based upon
the very good outcome observed in patients with symptomatic MM and good prognosis [50], as well
as upon a lower genomic complexity during the early phases of the disease that, together with a lower
tumor burden, might suggest a higher possibility of cure [51]. Moreover, better treatment feasibility is
expected in asymptomatic patients in good conditions. This rationale led to the design of clinical trials
for the treatment of high-risk SMM (Table 3).
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Table 3. Smoldering multiple myeloma: Selected clinical trials.
Protocol Phase Treatment Pts Response TTP/PFS/OS Toxicity (≥G3)
NCT00480363
QuiRedex [52] Phase III Rd vs. observation
Induction: 28-day cycle
(cycles 1–9) lenalidomide 25
mg p.o. days (D) 1–21 + dex
20 mg p.o. D1–4, 12–15
Maintenance: (cycles 1–24)
28-day cycle
Lenalidomide 10 mg D1–21
vs.
Observation
119
FU 73 months
Best response 26%
CR after
maintenance
Median TTP NR (HR
0.24)
3-year PFS 77%
3-, 5-year OS 94%, 88%
(HR 0.43)
vs.
median TTP 23 months
(p < 0.001)
3-year PFS 30% (p <
0.001)
3-, 5-year OS 80%, 71%,
(p = 0.03)
Neutropenia 5%
Thrombocytopenia 2%
Anemia 2%
Infection 6%
Asthenia 6%
Skin rash 3%
vs.
none
NCT01572480
120107 [53] Phase II
KRd induction
Rd maintenance
Induction: 28-day cycle
(cycles 1–8) carfilzomib
20/36 mg/m2 iv D1, 2, 8, 9,
15, 16 + lenalidomide 25 mg
p.o. D 1–21 + dex 20 mg
(cycles 1–4) and 10 (cycles
5–8) p.o. or iv D1, 2, 8, 9, 15,
16
Maintenance (cycles 1–24):
28-day cycle
lenalidomide 25 mg D1–21
12
CR 100%. MRD
neg (MFC 10−5 )
92%
No progression to MM
3-, 4-year PFS 94%, 70.6%
3-, 4- year OS: 100%
Hematologic:
Lymphopenia 39%
Neutropenia 28%
Anemia 22%
Thrombocytopenia 11%
Non-hematologic:
Diarrhea 17%
Lung infection 17%
Hypophosphatemia 11%
1 case of CHF
NCT02415413
GEM-CESAR
[54]
Phase II
KRd induction
ASCT
KRd consolidation
Rd maintenance
Induction: 28-day cycle
(cycles 1–6): carfilzomib
20/36 mg/m2 iv D1, 2, 8, 9,
15, 16 + lenalidomide 25 mg
p.o. D1–21 + dex 40 mg D1,
8, 15, 22
ASCT melphalan 200 mg/m2
Consolidation: KRd 2 cycles
Maintenance: 28-day cycle
lenalidomide 10 mg days
1–21 + 20 mg days 1, 8, 15,
22 for 2 years
90
ORR: 100%. ≥CR:
70%
MRD (NGF) 57%
30 months PFS 98%
Induction (G3-4):
Neutropenia 6%
Thrombocytopenia 11%
Infections 18%
Consolidation: Ongoing
Cancers 2019, 11, 2015 8 of 38
Table 3. Cont.
Protocol Phase Treatment Pts Response TTP/PFS/OS Toxicity (≥G3)
NCT03673826
HO147SMM Phase II
KRd vs. Rd
Rd maintenance
Induction:
(cycles 1–9) carfilzomib
20/36 mg/m2 iv D1, 2, 8, 9,
15, 16, lenalidomide 25 mg
p.o. D1–21, dexamethasone
20 mg p.o. (cycles 1–4) and
10 mg p.o. (cycles 5–9) D1,
8, 15, 22
vs.
(cycles 1–9) lenalidomide 25
mg p.o D1–21,
dexamethasone 20 mg p.o.
(cycles 1–4) and 10 mg p.o.
(cycles 5–9) D1, 8, 15, 22
Maintenance: (cycles 1–24)
lenalidomide 10 mg p.o.
days 1–21 of a 28-day cycle
120 NA NA NA
NCT03289299
ASCENT Phase II
Dara KRd + Rd
maintenance
Induction: 28-day cycle
(cycles 1–6) carfilzomib
20/36 mg/m2 iv D1, 2, 8, 9,
15, 16 + lenalidomide 25 mg
p.o. D1–21 + dex 40 mg D1,
8, 15, 22, daratumumab 16
mg/kg iv D1, 8, 15, and 22 of
cycles 1–2; D1 and 15 of
cycles 3–6;
Consolidation:
6 cycles, KR as in induction
+ dex 20 mg p.o. D1, 8, 15,
22 Daratumumab 16 mg/kg
iv D1 of cycles 7–12
vs.
ASCT
Maintenance: 12 cycles,
lenalidomide 10 mg p.o.
D1–21
+ daratumumab; 16 mg/kg
iv D1 of odd cycles for
cycles 13–24
83 NA NA NA
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Table 3. Cont.
Protocol Phase Treatment Pts Response TTP/PFS/OS Toxicity (≥G3)
NCT02697383
15-294 [55] Phase I
Ixazomib
dexamethasone
28-day cycle
(cycles 1–12) ixazomib 4 mg
on D1, 8, and 15, and
dexamethasone on days 1, 8,
15, and 22 (40 mg/week the
first 4 cycles, thereafter 20
mg/week)
14 ORR 64%
64% ORR (8 PR, and 1
VGPR) no patient
progressed to MM
Lung infection (14%)
NCT01441973
CA204-011 [56] Phase II Elotuzumab
(cycle 1) elotuzumab 20
mg/kg iv D1, 8 then [cycle
2—progressive disease]
Elotuzumab monthly q4
week
vs.
(cycle 1) elotuzumab 10
mg/kg iv D1, 8, 15, 22
(cycle 2—progressive
disease) elotuzumab
monthly q2 week
31 Both groups ORR10%
Both groups
2-year PFS 69%
Upper respiratory tract
infection 7%
vs.
Fatigue 6%
Diarrhea 6%
Insomnia 6%
NCT02279394
14-338 [57] Phase II
Elotuzumab Rd +
stem-cell
mobilization +
maintenance
Induction: 28-day cycle
(cycles 1–2) elotuzumab 10
mg/kg iv D1, 8, 15, 22 +
lenalidomide 25 mg p.o.
D1–21 + dex 40 mg p.o. D1,
8, 15, 22 (cycles 3–8):
elotuzumab 10 mg/kg iv D1,
15 + lenalidomide as in
cycles 1–2 + dex 40 mg p.o.
D1, 8, 15
Maintenance: 28-day cycle
(cycles 9–4) elotuzumab 10
mg/kg iv D
1 + lenalidomide as in
cycles 1–2
50 ≥VGPR 43% NA
Hypophosphatemia 34%
Neutropenia 26%
Lymphopenia 22%
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Table 3. Cont.
Protocol Phase Treatment Pts Response TTP/PFS/OS Toxicity (≥G3)
NCT02916771
16-313 [58] Phase II Ixazomib-Rd
Induction: 28-day cycle
(cycles 1–9): ixazomib 4 mg
p.o. D1, 8, 15 +
lenalidomide 25 mg
p.o. D1–21 + dex 40 mg p.o.
D1, 8, 15, 22
Maintenance: 28-day cycle
(cycles 10-24): ixazomib 4
mg p.o. D1, 8,
15 + lenalidomide 25 mg
p.o. D1–21
26 ≥VGPR 53.8% NA
Hypophosphatemia 13%
Lymphopenia 13%
Neutropenia 8.7% (G4
Neutropenia in 1 pt)
NCT01484275
CR100755 [59] Phase II
Siltuxumab vs.
placebo
(cycle 1—until progressive
disease): siltuximab 15
mg/kg iv every 4 weeks
vs.
observation
87 NA
1-year PFS: 84%
Median PFS: NR
vs.
1-year PFS: 74.4%
Median PFS: 23.8 months
Infections (5 patients in
siltuximab group and 6
patients in placebo group)
Urinary disorders (one
patient in the siltuximab
group and three patients in
the placebo group)
NCT02960555
2015-0148 Phase II Isatuximab
(cycles 1–30): 28-day cycle
isatuximab iv D1, 8, 15, and
22 of cycle 1, on D1 and 15
of cycles 2–6, and on D1 of
subsequent courses
61 NA NA NA
NCT02316106,
CENTAURUS
[60]
Phase II
Daratumumab iv
(3 arms, 41
patients each)
Daratumumab 16 mg/kg iv
in 8-week cycles
Long intensity:(cycle 1)
every 1 week; (cycle 2–3)
every other
week; (cycles 4–7) every 4
weeks; (cycles 8–20) every 8
weeks
Intermediate intensity:
(cycle 1) every 1 week and
(cycles 2–20) every 8 weeks
Short intensity: (cycle 1)
every week for 8 infusions
123
≥CR rate 7% in
combined Long
and Int arms
Long intensity
24-month PFS 90%
vs.
intermediate intensity
24-month PFS 82%
vs.
short intensity 24-month
PFS
75%
Long intensity serious
adverse events, 32%
≥G3 AE 44%
- Hypertension 7%
- Hyperglycemia 2%
vs.
intermediate intensity
serious adverse events 15%
≥G3 AE 27%
- Hypertension 5%
- Hyperglycemia 5%
vs.
short intensity
serious adverse events, 10%
≥G3 AE 15%
- Hypertension 3%
- Hyperglycemia 0%
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Table 3. Cont.
Protocol Phase Treatment Pts Response TTP/PFS/OS Toxicity (≥G3)
NCT03301220
AQUILA [61] Phase III
Daratumumab sc
for 3 years vs.
observation
Daratumumab sc injection
(daratumumab 1800 mg +
rHuPH20 [2000 U/mL])
once weekly for cycles 1
and 2 (D1, 8, 15, and 22 of
each week), every 2 weeks
for cycles 3–6 (D1 and 15),
and thereafter every 4
weeks (D1) until 39 cycles or
up to 36 months or PD
vs.
observation
390 NA NA NA
NCT01169337
E3A06 [62] Phase II–III
R vs. observation
(median FU 35
months)
Lenalidomide 25 mg p.o.
D1-21 in 28 days cycle until
PD
vs.
observation
180
Overall response
47.7% phase II
48.9% phase III
PFS 1 year
(98% vs. 89%),
PFS 2 years
(93% vs. 76%)
PFS 3 years
(91% vs. 66%)
G3/4 non-hematologic
AEs 28%:
- Infections 10%
- Fatigue 6.8%
- Hypertension 9%
G4 hematologic AEs
4.5%, primarily
neutropenia (n = 4),
cumulative incidence of
invasive SPMs 11.4%
(Len) and 3.5%
(observation).
D, day; Pts, patients; R, Len, lenalidomide; d, dex, dexamethasone; FU, follow-up; TTP, time to progression; PFS, progression-free survival; OS, overall survival; G, grade; P, p-value;
MM, multiple myeloma; K, carfilzomib; ORR, overall response rate; Dara, daratumumab; ASCT, autologous stem-cell transplantation; NA, not available; NR, not reached; iv, intravenous;
D, day; AE, adverse event; sc, subcutaneous; p.o., orally; HR, hazard ratio; CR, complete response; PR, partial response; VGPR, very good PR; PD, progressive disease; CHF, congestive
heart failure; SPMs, second primary malignancies; MRD, minimal residual disease; neg, negative.
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In the phase III randomized QuiRedex study, 119 high-risk SMM patients [52] received
lenalidomide–dexamethasone (Rd) vs. observation. After a median follow-up of 75 months, the median
TTP was not reached in the Rd group (n = 57) vs. 23 months in the observation group (n = 62, HR 0.24,
p < 0.0001). An advantage in OS in the Rd arm was also detected (HR 0.43, p = 0.024). Interestingly,
survival was similar in the two groups for patients who had previously received subsequent lines of
therapy at the progression to active disease (HR 1.34, p = 0.50). The Rd combination showed acceptable
levels of toxicity: Grade ≥3 adverse events (AEs) were infection (6%), asthenia (6%), neutropenia
(5%), and skin rash (3%). During treatment, two patients treated with lenalidomide died of infection.
A higher rate of second primary malignancies (SPMs) was detected in the Rd group (10%) vs. the
observation group (2%). Of note, progression was defined by classical CRAB criteria (hyperCalcemia,
Renal failure, Anemia, and Bone lesions) and advanced imaging techniques at screening were not
performed, thus suggesting that the study also included patients who would currently be classified as
having symptomatic MM.
The efficacy of lenalidomide was also shown in the phase II/III E3A06 study, in which lenalidomide
was compared to observation in SMM [62]. After a median follow-up of 35 months in phase III of
the trial, the overall response rate (ORR) was 50% in the R group and 0% in the observational
group. One-year, 2-year, and 3-year PFS were respectively 98%, 93%, and 91% in the R group,
favorably comparing with respectively 89%, 76%, and 66% in the observational arm (HR 0.28,
p = 0.002). Among lenalidomide-treated patients, grade 3/4 non-hematologic toxicities occurred in
28% of the phase III patients, with hypertension and infections being most common toxicities.
However, no difference in scores regarding the quality of life was noted between the lenalidomide and
the observational groups. In this trial, SPMs were detected in 11.4% of lenalidomide-treated patients
vs. 3.4% of patients in the observational group.
In this setting, another attractive drug is the second-generation PI ixazomib, which is
characterized by a convenient oral administration and shows good safety results. In a phase I
study, ixazomib associated with dexamethasone showed good tolerability and high response rate
(ORR 64%, PR 57%, and VGPR 14%) [55]. A phase II study exploring the entirely oral triplet
ixazomib–lenalidomide–dexamethasone confirmed the good tolerability profile and efficacy of this
combination, with a 58% of ≥VGPR (CR 19%, VGPR 34%) [58].
MAbs were also evaluated for the treatment of SMM. The anti-SLAMF7 elotuzumab as single
agent showed a low response rate (ORR 10%, minimal response (MR) 29%), with a 2-year PFS of 69%,
while first data of the combination with Rd showed a ≥VGPR rate of 43% [56,57].
The phase II CENTAURUS trial evaluated daratumumab alone in 123 patients with three
different dose schedules and durations (long intense, intermediate, short intense; Table 3) [60]. At a
median follow-up of 25.9 months, ≥VGPR rates were higher in the long intense and intermediate arms
compared to the short intense arm (29%, 25%, and 18%, respectively). The 24-month PFS rates were 90%,
82%, and 75% in the three arms. Grade ≥3 AEs occurred in 44% (long intense), 27% (intermediate), and
15% (short intense) of patients. The most frequent grade 3–4 AEs were hypertension and hyperglycemia.
The subcutaneous formulation of daratumumab is also being explored in a randomized phase III trial
against active monitoring in this setting (NCT03301220). Another anti-CD38 mAb, isatuximab, is under
evaluation (NCT02960555).
More intense regimens using three- or four-drug combinations ±ASCT were used in the high-risk
SMM setting, aiming at the eradication of MM.
In a small cohort of 12 high-risk SMM patients, Korde and colleagues demonstrated that
carfilzomib–lenalidomide–dexamethasone (KRd) induced deep responses (≥CR 100%) and MRD
negativity (92% by MFC); after a median follow-up of 15.9 months, none of the patients progressed
to MM [53]. Interestingly, the same regimen administered in the NDMM setting produced a lower
rate of deep responses (≥CR 56%), suggesting that high-risk SMM patients can be more sensitive to
treatment [53].
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In the single-arm, phase II GEM-CESAR trial, patients received KRd as induction, ASCT, KRd as
consolidation and maintenance therapy with Rd. After a median follow-up of 32 months (8–128),
the 30-month PFS was 93% and each phase of therapy was associated with increasing rates of MRD
negativity evaluated by NGF (sensitivity 3 × 10−6; 31% after induction, 56% after ASCT, 63% after
consolidation). During induction, the most common G≥3 AEs were infections (18%), skin rash
(9%), neutropenia (6%), and thrombocytopenia (11%). Cardiac AEs were rare: 1 grade 1 atrial
fibrillation, 1 cardiac failure secondary to respiratory infection, and 3 cases of hypertension during
consolidation [54].
Another ongoing randomized phase II study (HO147SMM) is comparing KRd to Rd, but no data
are available yet.
The addition of the anti-CD38 mAb daratumumab to KRd induction and consolidation is being
evaluated in the ASCENT study (NCT03289299), which is now recruiting patients. A randomized
comparison of daratumumab–Rd vs. Rd in the context of high-risk SMM is also ongoing (NCT03937635).
4. Treatment of Symptomatic NDMM
The first efforts aiming at a curative approach in NDMM were done by the University of
Arkansas group in the 1990s, developing a program called Total Therapy (TT) using a series of
non-cross-resistant induction regimens, 2 cycles of high-dose chemotherapy, followed by ASCT and
maintenance treatment [63]. Toxicity concerns and the unavailability of novel agents hindered the
success of this approach, although the long-term follow-up of treated patients (median 21 years)
showed a plateau in the survival curves with an estimated cure rate of 9% based on PFS data and of
18% based on the duration of CR [64].
Currently, general treatment approaches in NDMM patients are tailored upon their eligibility for
high-dose therapy (HDT) and ASCT [65].
4.1. ASCT-Eligible Patients
The current therapeutic approach includes sequential induction therapy and ASCT ±
consolidation, followed by maintenance. Induction is typically administered for 4–6 cycles prior to
ASCT [66]. The introduction of the PI bortezomib increased the response rate compared to classical
chemotherapy [67], and is now a backbone of treatment. The addition of a third drug to the
bortezomib–dexamethasone (Vd) combination (i.e., thalidomide [VTd], cyclophosphamide [VCd],
lenalidomide [VRd], doxorubicin [PAD]) increased the depth of response [68]. In a head-to-head
comparison, VTd was superior to VCd as induction prior to HDT–ASCT in terms of ORR (92% vs.
83%) and ≥VGPR rate (66% vs. 56%) [69], demonstrating that even with first-generation novel agents,
the combination of a PI and an IMiD was beneficial.
In phase III trials, VRd induction was tested in the PETHEMA and Intergroupe Francophone du
Myélome (IFM) 2009 studies (Table 4).
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Table 4. Newly diagnosed multiple myeloma: selected clinical trials enrolling transplant-eligible patients.
Protocol Phase Treatment Subjects Response TTP/PFS/OS Toxicity (≥G3)
NCT01206205
IFM2008 [70] Phase II
VRd induction
Stem-cell
mobilization
ASCT
VRd
consolidation
R maintenance
Induction 21-day cycles (cycles
1–3)
Bortezomib iv 1.3 mg/m2 D1, 4, 8,
and 11
Lenalidomide p.o. 25 mg D1–14
Dexamethasone p.o. 40 mg D1, 8,
15
Stem-cell harvest
Consolidation 21-day cycles
(cycles 1–3)
Bortezomib iv 1.3 mg/m2 D1, 4, 8,
and 11
Lenalidomide p.o. 25 mg D1–14 +
dex p.o. 40 mg D1, 8, 15
Maintenance
Lenalidomide p.o. 10 mg per day
for the first 3 months, a possible
dose increase to 15 mg for 1 year
31
After induction
58% ≥VGPR
23 % ≥CR
16% MRD neg MFC
(10−4–10−5)
After ASCT
70% ≥VGPR
47%≥CR
54% MRD neg MFC
(10−4–10−5)
After consolidation
87% ≥VGPR
50 ≥CR
58% MRD neg MFC
(10−4–10−5)
Best response (after
maintenance)
84% ≥VGPR
58% ≥ CR
68% MRD neg MFC
(10−4–10−5)
Estimated 3-year
PFS 77% and OS
100% (median
FU 39 months)
Neutropenia 65%
Thrombocytopenia
19%
Anemia 3%
Infections 6%
NCT00507442
EVOLUTION
[71]
Phase II
randomized
VRd (n = 42) vs.
VRCd (n = 48)
vs.
VCd (n = 33)
Induction 21-day cycles
(cycles 1–8)
Bortezomib 1.3 mg/m2, days 1, 4,
8, 11
Dexamethasone 40 mg, D1, 8, 15
Cyclophosphamide 500 mg/m2,
D1, 8
Lenalidomide p.o., 15 mg in
VRCd and 25 mg in VRd D1–14
Maintenance 6-week cycles (cycles
1–4) Bortezomib 1.3 mg/m2, D1, 8,
15, 22
Stem-cell mobilization any time
after 2 cycles
ASCT any time after 4 cycles
140
VRd best response
61% ≥VGPR
21% CR
VRCd best response
54% ≥VGPR
21% CR
VCd best response
24% ≥VGPR
10% CR
1-year PFS
83% VRd
86% VRCd
93% VCd
100% VCd-mod
1-year OS
estimate
92% VRCd arm
100% for the
other three arms
VRd
Neuropathy 17%
vs.
VRCd
Neuropathy 13%
vs.
VCd
Neuropathy 9%
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Table 4. Cont.
Protocol Phase Treatment Subjects Response TTP/PFS/OS Toxicity (≥G3)
NCT01554852
MyelomaXI
[72,73]
Phase III
randomized
Transplant
eligible:
CTd vs. CRd vs.
KCRd induction
CVd
intensification vs.
no intensification
Mel200 ASCT
Lenalidomide
maintenance vs.
observation
Transplant eligible:
Induction
CTd: 21-day cycle
cyclophosphamide 500 mg p.o.
D1, 8, 15
thalidomide 50 mg p.o.
continuously D1–21
dexamethasone 40 mg p.o. D1–4,
12–15
CRd: 28-day cycle
cyclophosphamide 500 mg p.o.
D1, 8
lenalidomide 25 mg p.o. D1–21
dexamethasone 40 mg p.o. D1–4,
12–15
KCRd: 28-day cycle
carfilzomib 36 mg/m2 i.v. D1, 2, 8,
9, 15, and 16
cyclophosphamide 500 mg p.o.
D1, 8
lenalidomide 25 mg p.o. D1–21
dexamethasone 40 mg p.o. D1–4,
8, 9, 15, and 16
Consolidation
CVd: 21-day cycles
Bortezomib i.v. 1.3 mg/m2 D1, 4, 8,
and 11
cyclophosphamide 500 mg p.o.
D1, 8, and 15
Dexamethasone p.o. 20 mg D1, 2,
4, 5, 8, 9, 11, and 12
Maintenance
Lenalidomide p.o. 10 mg D1–21
1056
Post-induction
CTd
53% ≥VGPR
11% MRD neg (MFC
10−4–10−5)
CRd
65% ≥VGPR
21% MRD neg
KCRd
82% ≥VGPR
55% MRD neg
3-year PFS
50.3% CTd/CRd
64.5% KCRd
- Neutropenia
12.8% CTd
22.3% CRd
16.4% KCRd
-
Thrombocytopenia
1.2% CTd
2.3% CRd
8.4% KCRd
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Table 4. Cont.
Protocol Phase Treatment Subjects Response TTP/PFS/OS Toxicity (≥G3)
NCT01191060
IFM2009 [74] Phase III
VRd induction
arm
VRd
consolidation
arm
ASCT
Induction: 21-day cycles (cycles
1–3) Bortezomib i.v. 1.3 mg/m2 D1,
4, 8, and 11
Lenalidomide p.o. 25 mg D1–14
Dexamethasone p.o. 20 mg D1, 2,
4, 5, 8, 9, 11, and 12
Stem-cell mobilization with
cyclophosphamide and G-CSF
Consolidation (cycles 4–8) VRd
reduced dex 10 mg (VRd-alone
group)
vs.
Melphalan 200 mg/m2 ASCT + 2
cycles of
VRd reduced dex 10 mg
(transplantation group)
Maintenance
Lenalidomide p.o. 10 mg per day
for the first 3 months, a possible
dose increase to 15 mg for 1 year
700
VRd arm
After induction
45% ≥VGPR
After consolidation
≥69% VGPR
Best response (after
maintenance)
77% ≥VGPR
48% CR
of which 65% MRD neg
vs.
VRd–ASCT
After induction
47% ≥VGPR
After consolidation
78% ≥VGPR
Best response
88% ≥VGPR
59% CR
of which 79% MRD neg
Median PFS 50
vs. 36 months
OS 4years
81% vs. 82%
Neutropenia (47%
vs. 92%)
Gastrointestinal
disorders (7% vs.
28%)
Infections (9% vs.
20%)
NCT01916252
GEM2012
MENOS65 [75]
Phase III
VRd 6 cycles
Stem cell
mobilization
after 3 induction
cycles
Mel200-ASCT
vs.
BuMel-ASCT
VRd 2 cycles
post-transplant
consolidation
Induction (cycles 1–6)
Bortezomib 1.3 mg/m2 sc D1, 4, 8,
11 Lenalidomide 25 mg/day D1–21
Dexamethasone 40 mg on D1–4
and 9–12 at 4 weeks
ASCT
Melphalan 200 mg/m2 iv D 2
vs.
Busulfan 9.6 mg/kg + Melphalan
140 mg/m2
Consolidation
(cycles 7–8) same schedule as
induction
458
After induction
29% VGPR
39% CR
28% sCR
34% MRD-neg (by NGF)
After ASCT
27% VGPR
49% CR
36% sCR
53% MRD neg
After consolidation
58% MRD neg
NA
Induction
Neutropenia 11%
Thrombocytopenia
6%
Hepatic 4%
Skin 3%
Neuropathy 1%
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Table 4. Cont.
Protocol Phase Treatment Subjects Response TTP/PFS/OS Toxicity (≥G3)
NCT01029054
UMCC 2009.056
[8]
Phase I/II
Phase II
extended
Phase I
KRd without
ASCT induction
and KRd
maintenance
Phase II
KRd induction
Mobilization
ASCT/Mel200
KRd
consolidation
KRd
maintenance
Phase I/II
Induction (cycles 1–8) Carfilzomib
iv 20/36 mg/m2 D1, 2, 8, 9, 15, 16
(20 mg/m2 given on cycle 1, D1)
Lenalidomide p.o. 25 mg D1–21
Dexamethasone p.o. 40 mg/week
Maintenance (cycles 9–24)
Carfilzomib 36 mg/m2 D1, 2, 15, 16
Lenalidomide p.o. same dose of
C8 D1–21
Dexamethasone p.o. 20 mg
weekly
Phase II
Induction (cycles 1–4)
Carfilzomib iv 20/36 mg/m2 D1, 2,
8, 9, 15, 16 (20 mg/m2 given on
cycle 1, D1)
Lenalidomide p.o. 25 mg D1–21
Dexamethasone p.o. 40 mg/week
Stem-cell collection using G-CSF
and plerixafor
ASCT Melphalan 200 mg/m2
conditioning
Consolidation (cycles 5–8)
Carfilzomib i.v. 36 mg/m2 D1, 2, 8,
9, 15, 16
Lenalidomide p.o. 15 mg D1–21
(with option to escalate to 25 mg)
Dexamethasone p.o. 20 mg
weekly
Maintenance (cycles 9–18)
Carfilzomib 36 mg/m2 D1, 2, 15, 16
Lenalidomide p.o. same dose of
cycle 8 D1–21
Dexamethasone p.o. 20 mg
weekly
Lenalidomide as single-agent
off-study after C18.
53 (phase I/II)
76 (phase II)
Phase I/II
Post-induction (C8)
55% sCR
Phase II
Post-consolidation (C8)
96% ≥VGPR, 73% CR
69% sCR.
Post-consolidation (C8)
82% MRD neg (MFC) (N =
33) 66% MRD neg (NGS) (N
= 29)
Post-Maintenance (C18)
90% MRD neg (MFC) (N =
20) 71% MRD neg (NGS) (N
= 16)
Phase I/II
4- year PFS 63%
4-year OS 93%
Phase II
2-year PFS 97%
and 2-year OS
99%
(median FU 17
months)
Phase II
Lymphopenia 28%
Neutropenia 18%
Infections 8%
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Table 4. Cont.
Protocol Phase Treatment Subjects Response TTP/PFS/OS Toxicity (≥G3)
NCT01402284
110221 [53] Phase II
KRd induction
R maintenance
Induction (cycles 1–8) Carfilzomib
iv 20/36 mg/m2, D1, 2, 8, 9, 15, 16
Lenalidomide 25 mg p.o. D1–21
Dexamethasone 20 mg (cycles 1–4)
and 10 (cycles 5–8) p.o. or iv D1, 2,
8, 9, 15, 16 then
Maintenance (cycles 1–24)
lenalidomide 25 mg D1–21
45
62% MRD neg (calculated
on NGS-evaluable NDMM
patients)
18-month PFS:
100% vs. 84%
Lymphopenia 34%
Thrombocytopenia
11%
Neutropenia 15%
Anemia 12%
Infection 6%
Cardiac 5%
Vascular 6%
NCT02203643
FORTE [9] Phase II
KCd-ASCT-KCd
(arm A),
KRd-ASCT- KRd
(arm B),
KRd 12 cycles
(arm C)
Induction (cycles 1–4) Carfilzomib
36 mg/m2 D1, 2, 8, 9, 15, and 16 of
a 28-day cycle; lenalidomide p.o.
25 mg D1–21
Dexamethasone 20 mg D1, 2, 8, 9,
15, and 16) or
Cyclophosphamide 300 mg/m2 on
D1, 8, and 15
Intensification
ASCT/mel200 or 4 KRd cyles
(cycles 4–8)
Consolidation (cycles 8–12)
4 cycles same as induction
Maintenance
KR vs. R (random)
474
Pre-maintenance response
rates: ≥VGPR:
76% Arm A
89% Arm B
87% Arm C
sCR:
32% Arm A
44 % Arm B
43 % Arm C
Pre-maintenance MRD neg
MFC
42% Arm A
58% Arm B
54% Arm C
NA
Dermatologic
1–13%
Neutropenia
15–20%
Thrombocytopenia
8–15%
Infections 12–14%
Increased liver
enzymes 1–10%
Hypertension
3–8%
Cardiac 2–3%
NCT02874742
GRIFFIN [76] Phase II
Dara-VRd
induction
Mobilization
ASCT
Dara-VRd
consolidation
Dara-R
maintenance
Induction (cycles 1–6)
Lenalidomide 25 mg p.o. D1–14
Bortezomib 1.3 mg/m2 sc D1, 4, 8,
and 11
Dexamethasone 40 mg weekly
Daratumumab 16 mg/kg iv D1, 8,
and 15 of cycles 1–4 and on D1 of
cycles 5–6.
Maintenance (C7–32)
lenalidomide 10 mg p.o. daily (15
mg beginning at cycle 10 if
tolerated) on D1–21 every 28 days
and Dara 16 mg/kg iv every 56
days;
Maintenance lenalidomide may
be continued beyond C32
207 (safety run in
16 pts)
Post-consolidation
(Dara–VRd)
91% ≥VGPR
52% ≥CR of which
59% MRD neg
vs.
(VRd)
73% ≥VGPR
42% ≥CR of which
24% MRD neg
NA (FU 13.5
months)
>10%
Cytopenia similar
in two arms
40% of Dara
infusion-related
reaction (mainly
G1–2)
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Table 4. Cont.
Protocol Phase Treatment Subjects Response TTP/PFS/OS Toxicity (≥G3)
NCT02541383
CASSIOPEIA
[77]
Phase III
Dara-VTd-ASCT-
Dara-VTd vs.
VTd-ASCT-VTd
Maintenance
Daratumumab
vs. observation
Induction (cycles 1–4) and
consolidation (cycle 5–6)
Bortezomib 1.3 mg/m2 D1, 4, 8, 11
Thalidomide 100 mg daily p.o. in
all cycles
Dexamethasone 40 mg p.o. or iv
D1, 2, 8, 9, 15, 16, 22, and 23 of
induction cycles 1 and 2 and D1
and 2 of induction cycles 3 and 4
and 20 mg on D8, 9, 15, 16 of
induction cycles 3–4 and D1, 2, 8,
9, 15, and 16 of both consolidation
cycles.
Daratumumab iv 16 mg/kg once
weekly in induction cycles 1 and 2
and once every 2 weeks during
induction cycles 3 and 4 and
consolidation
Stem-cell mobilization with
cyclophosphamide (3 g/m2)
ASCT
Mel200 mg/m2 iv conditioning
Maintenance
Daratumumab (16 mg/kg) every 8
weeks until disease progression or
for a maximum of 2 years
vs.
observation
1085
Post-consolidation
(Dara–VTd)
83% ≥VGPR
10% CR
28.9% sCR
64% MRD neg (MFC)
39% MRD neg (NGS)
vs.
(VTd)
78% ≥VGPR
6% CR
20.3% sCR
44% MRD neg (MFC)
23% MRD neg (NGS)
Probability: 18
months PFS
(Dara–VTd) 93%
vs.
(VTd)
85%
OS NR
Neutropenia 28%
vs. 15%
Thrombocytopenia
11 vs. 7%
Neuropathy 9% vs.
9%
GIT 16%
Reaction infusion
4% in Dara–VTd
NCT01998971
MMY1001 [11] Phase Ib Dara-KRd
Daratumumab 16 mg/kg QW for
cycles 1–2, Q2W for cycles 3-6,
and Q4W (1st dose of Dara split
over 2 days)
Carfilzomib 20/36 mg/m2 iv
weekly D1, 8 and 15 of each
28-day cycle (20 mg/m2 on cycle 1,
D1) for ≤13 cycles or elective
discontinuation for ASCT
Lenalidomide p.o. 25 mg D1–21
and Dexamethasone 20–40 mg per
week
22
Best response
33% VGPR
14% CR
43% sCR
1-year PFS 95%
Lymphopenia 50%
Neutropenia 23%
1 (5%)
cardiac grade 3
TEAE was
observed
(congestive heart
failure)
Cancers 2019, 11, 2015 20 of 38
Table 4. Cont.
Protocol Phase Treatment Subjects Response TTP/PFS/OS Toxicity (≥G3)
NCT01217957
C16005 [78] Phase I/II
Ixa-Rd induction
ASCT ±
Ixa maintenance
Induction 28-day cycles
(cycles 1–12) Ixazomib p.o. 4 mg
D1, 8, and 15
Lenalidomide p.o. 25 mg D1–21
Dexamethasone p.o. 40 mg D1, 8,
15, and 22
Discontinuation→ ASCT
Maintenance
Only for patients who did not
proceed to ASCT:
Single-agent ixazomib, given at
the last tolerated dose during
induction
65
63% ≥VGPR
32% CR
MRD neg 12.5% (MFC)
Median PFS 35.4
months
Neutropenia 14%
Thrombocytopenia
9%
GIT 6%
NDMM, newly diagnosed multiple myeloma; pts, patients; V, bortezomib; R, lenalidomide; d, dex, dexamethasone; C, cyclophosphamide; K, carfilzomib; T, thalidomide; iv, intravenous;
D, day; ASCT, autologous stem-cell transplantation; Mel200, melphalan at 200 mg/m2; Bu, busulfan; Ixa, ixazomib; p.o., orally; G-CSF, granulocyte colony-stimulating factor; Dara,
daratumumab; Pts, patients; PR, partial response; VGPR, very good PR; CR, complete response; sCR, stringent CR; MRD, minimal residual disease; MFC; multiparameter flow cytometry
NGS, next-generation sequencing; N, number; neg, negative; TTP, time to progression; PFS, progression-free survival; OS; overall survival; FU, follow-up; mod, modified; NA; not available;
NR, not reached; G, grade AE, adverse event; TEAE; treatment-emergent AE; GIT, gastrointestinal toxicity. QW, given every week; Q2W, given every two weeks; Q4W, given every 4 weeks.
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No randomized trial directly compared VRd vs. VTd induction, although a recent integrated
analysis of French and Spanish trials was performed (VRd: PETHEMA, GEM 2012, and IFM 2009;
VTd: GEM2005 and IFM 2013-04) [79]. In the Spanish studies, after 6 cycles of induction, the ≥VGPR
rate was 66.3% vs. 51.2% (p = 0.003) in VRd vs. VTd groups. In the French studies, after 4 cycles of
induction, the ≥VGPR rate was similar between VRd vs. VTd groups (57.1% vs. 56.5%). The safety
profile of VRd was better than that of VTd in both Spanish and French studies, with a lower rate of
polyneuropathy (PNP).
High-dose melphalan (200 mg/m2, MEL200) followed by ASCT is currently a standard approach
in transplant-eligible patients, due to the longer PFS showed in randomized clinical studies comparing
ASCT vs. novel agent-based therapy [50,74,80,81], but the role of double vs. single ASCT is still an
open issue. The EMN02/HO95 phase III trial showed a benefit in the double ASCT arm in terms of
PFS (3-year PFS 73% vs. 64% in double vs. single ASCT); this effect was particularly evident in the
high cytogenetic risk group, where an OS benefit was also noticed [82]. Similarly, in a meta-analysis
including three phase III trials, after a median follow-up of 10 years, double ASCT was significantly
better than single ASCT in terms of PFS and OS. Consistent with the EMN02/HO95 data, the benefit was
particularly evident in the high-risk group [82], suggesting that, in this patient population, a double
ASCT is advisable. Nevertheless, the STAMINA trial did not show any difference in PFS or OS of
patients receiving double vs. single ASCT. It is always difficult to perform comparisons between
different trials, but the better and prolonged induction (VRD) used in the majority of the patients
enrolled in the STAMINA study (whereas 3-4 cycles of VCD were used in the EMN02 study) and the
lower compliance to the second ASCT procedure reported in the same study can partially explain the
different results [83].
Many trials explored consolidation regimens with the rationale to deepen patient response. In the
most recently published PETHEMA study, VRd induction, ASCT, and VRd consolidation produced
a ≥CR rate of 58% (46% sCR, 12% CR) [75]. These data are consistent with the IFM phase II and phase
III studies using VRd consolidation. In the IFM2009 study, VRd consolidation after VRd induction and
ASCT showed a similar trend, with the≥CR rate increasing from 27% during the induction phase, to 47%
after ASCT to 50% after consolidation (sCR 40%, CR 10%) (Table 4) [70]. Response deepened over time,
as well as MRD negativity. In the PETHEMA study, MRD by NGF with a cut-off sensitivity of 3 × 10−6
progressively increased from 34.5% post-induction to 53.4 % post-ASCT, to 58% after consolidation [75].
The phase III STAMINA and EMN02/HO95 trials were designed to evaluate the role of consolidation
vs. no consolidation in a randomized fashion. In the STAMINA trial, the 38-month probability for
PFS was respectively 58% with single ASCT + VRd consolidation, 58% with tandem ASCT and no
consolidation, and 53% with single ASCT and no consolidation, with no statistical differences [83].
In the EMN02/HO95 study, VRd consolidation after ASCT/bortezomib–melphalan–prednisone (VMP)
showed a PFS advantage, with a 5-year PFS of 48% in the VRd consolidation arm and 41% in the no
consolidation arm [83,84].
In transplant-eligible patients, maintenance therapy is the standard approach after ASCT ±
consolidation. A meta-analysis of three phase III trials randomizing patients to lenalidomide vs.
observation/placebo showed a significant benefit in the lenalidomide arm in terms of PFS (median,
53 months vs. 24 months, HR 0.48; p = 0.001) and OS (not reached (NR) vs. 86 months, HR 0.75;
p = 0.001) [85]. More recently, the Myeloma XI study confirmed the advantage of lenalidomide
maintenance vs. observation after ASCT (median PFS 57 vs. 30 months, HR 0.48, p < 0.0001; 3-year
OS 87.5% vs. 80.2%, HR 0.69, p = 0.01) [86]. Maintenance with lenalidomide can also further deepen
the response, with 27–30% of MRD-positive patients becoming MRD-negative during treatment [87].
Besides its efficacy, the tolerability of continuous lenalidomide maintenance is an important issue.
In the meta-analysis, about 30% of subjects receiving lenalidomide experienced a treatment-related
AE that led to discontinuation. Moreover, a higher incidence of SPMs in the lenalidomide arm was
reported, although it was outweighed by the advantage of a better disease control [85]. Although the
optimal duration is currently considered to be until progressive disease, the median actual duration is
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generally around 2–3 years [85], with retrospective data showing a benefit in patients continuing the
drug for at least 2 years [88,89]. However, there are currently no randomized prospective data showing
evidence that lenalidomide until progressive disease is better than its administration for a prolonged
but fixed duration [74].
Maintenance with lenalidomide alone showed conflicting results in high-risk patients [85,86],
and the addition of PIs was suggested to be beneficial [90]. In a phase III trial [91], long-term
treatment with bortezomib showed to abrogate the negative effect of deletion 17p [92–94].
Moreover, in a randomized study, the administration of the second-generation PI ixazomib as
post-ASCT maintenance improved PFS compared to placebo and showed a similar effectiveness
for both standard- and high-risk patients [95].
The high rate of deep responses (CR and MRD negativity) obtained after this sequential first-line
treatment could further be improved by incorporating the second-generation irreversible PI carfilzomib
or adding a fourth drug class, such as the anti-CD38 mAbs.
The incorporation of carfilzomib into first-line treatment was tested in several trials
(Table 4) [53,96–98]. In the randomized phase II FORTE trial, carfilzomib was combined either
with lenalidomide (KRd) or cyclophosphamide (KCd) with or without ASCT (arm A KCd–ASCT–KCd;
arm B KRd–ASCT–KRd; arm C KRd-12 cycles), followed by maintenance with KR or R. After a median
follow-up of 26 months, the post-consolidation response rates and MRD negativity were significantly
higher in the two KRd arms (B and C) than in the KCd arm (A): ≥VGPR rate was 74% (arm A), 87% (arm
B), and 87% (arm C), and the ≥CR rate 38% (arm A), 50% (arm B), and 52% (arm C). The MRD negativity
rate by MFC 10−5 after consolidation was respectively 41% (arm A), 58% (arm B), and 54% (arm C) [99].
The main non-hematologic grade ≥3 AEs were hypertension (8% KRd-12 vs. 3% KRd–ASCT and
KCd–ASCT), cardiac AEs (2% KRd-12 vs. 3% KRd–ASCT vs. 3% KCd–ASCT), infections (13% KRd-12
vs. 10% KRd–ASCT vs. 9% KCd–ASCT), and hepatic AEs (10% KRd-12 vs. 8% KRd–ASCT vs. 1%
KCd–ASCT) [99].
Despite similar MRD negativity rates, a lower number of early relapsing patients was noted in
the KRd–ASCT arm than in the KRd-12 arm. This was observed in intermediate + high-risk patients,
but not in standard-risk patients, suggesting that, despite the use of second-generation PIs upfront,
ASCT could still play a role in this patient population [9].
The addition of an anti-CD38 antibody to triplet regimens has been explored in several trials as
well. In the phase III trial CASSIOPEIA, daratumumab–VTd (Dara–VTd) induction-ASCT–Dara–VTd
was superior to VTd-ASCT-VTd in terms of response rate after consolidation, with ≥VGPR rate of
83% vs. 78%, CR rate of 10% vs. 6%, and sCR rate of 28.9% vs. 20.3%. MRD negativity (10−5)
after consolidation was reached in 64% vs. 44% of patients in the Dara–VTd vs. VTd arms; PFS
was significantly improved in the Dara–VTd group, as compared with the control group (HR 0.47,
95% confidence interval (CI) 0.33–0.67, p < 0.0001) [77].
The phase II GRIFFIN study compared Dara–VRd to VRd alone (Table 4). Dara–VRd improved
the sCR rate by end of consolidation (42.4% vs. 32.0%). Overall, post-consolidation response was
better in the Dara–VRd arm (≥VGPR 91%, ≥CR 52%, of which 59% MRD-negative) compared to the
VRd arm (≥VGPR 73%, ≥CR 42%, of which 24% MRD-negative); MRD negativity was achieved in 44%
of patients in the Dara–VRd arm after consolidation (10−5 threshold by NGS) [76].
A phase Ib study evaluated the addition of daratumumab to carfilzomib-based induction
(Dara–KRd). Serious AEs occurred in 46% of patients. The most common grade 3–4 AEs were
lymphopenia (50%) and neutropenia (23%); 1 cardiac grade 3 AE was observed (congestive heart
failure). In 22 treated patients, ORR was 100% (CR 5%, ≥VGPR 86) [11].
Similarly, the addition of isatuximab to KRd is being investigated in the phase II GMMG-CONCEPT
study. In the safety run-in phase (10 patients), the overall safety profile was consistent with
those previously reported with KRd and isatuximab. Non-hematologic grade ≥3 AEs were
treatment-unrelated cerebral vascular disorder (2 patients), self-limiting ventricular tachycardia
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(1), and diarrhea (1). Three patients experienced a grade 2 infusion-related reaction (IRR) during the
first infusion of isatuximab [100].
Quadruplet regimens not including mAbs may allow to achieve deep responses in the majority
of patients, preserving the opportunity to use mAbs after induction ± ASCT in patients not
achieving MRD negativity. Bortezomib–lenalidomide–cyclophosphamide–dexamethasone
(VRCd) produced a ≥VGPR rate of 33% after 4 induction cycles [71],
while carfilzomib–lenalidomide–cyclophosphamide–dexamethasone (KRCd) produced a ≥VGPR
rate of 82% (MRD negativity 55% at 10−4–10−5 sensitivity by flow cytometry) after a median of
4 induction cycles (range 1–12) in transplant-eligible patients [72].
In a small group of patients, the addition of the second-generation oral PI ixazomib to Rd (Ixa–Rd)
during induction followed by ASCT or by ixazomib maintenance induced a good response, with 63%
of patients achieving ≥VGPR and 12% MRD negativity. However, responses were not as deep as those
reached in patients treated with upfront daratumumab or carfilzomib, making Ixa–Rd less appealing
from a curative perspective [78].
4.2. ASCT-Ineligible Patients
ASCT-ineligible patients are a heterogeneous population. Scores predicting mortality and the
risk of treatment toxicity in elderly patients have been assessed. Evidence from clinical trials [101]
suggested that frailty-adapted therapies should be applied and that mainly fit patients can benefit
from strategies aiming at the deepest possible response, due to higher toxicities with similar therapies
in intermediate–fit/frail patients that in the end hamper the effectiveness of treatment itself [102,103].
The standard first-line treatment schemes for elderly patients are VMP, Rd, and VRd. In the phase
III VISTA trial, VMP was superior to melphalan-prednisone (MP) in terms of CR rate, PFS, and OS
(median 56 months vs. 43 months) [104,105].
Continuous Rd significantly increased PFS and OS compared to MPT and also prolonged PFS
(but not OS) compared to Rd18 (median PFS 26 months for Rd vs. 21 months for Rd18 and 21.9 months
for MPT; 4-year estimated OS 59% for Rd vs. 56% for Rd18 and 51% for MPT). Rd was also generally
better tolerated than MPT [106]. In a phase III clinical trial specifically designed for intermediate–fit
patients, according to the IMWG frailty score, continuous Rd was compared to Rd induction for 9 cycles
followed by R maintenance alone at lower doses: PFS was superimposable, with a better tolerability
with Rd–R [107].
VRd was also prospectively compared to Rd in the SWOGS0777 trial (Table 5),
which, however, was not restricted to elderly patients (median age 63 years) [108]. The addition
of bortezomib to Rd resulted in significantly improved PFS (43 months vs. 30 months in the Rd group;
p = 0.0018) and OS (75 months vs. 64 months in the Rd group; p = 0.025). Regarding safety, the VRd
combination showed higher rates of grade ≥3 AEs (82 vs. 75%), neurological toxicities (33% vs. 11%),
and discontinuation (23% vs. 10%). The high neurological toxicity could be due to the two-weekly
intravenous infusion of bortezomib used in this trial. In a small phase II study [109], a modified
VRd, including lower lenalidomide doses (15 mg) and weekly subcutaneous bortezomib (“VRd lite”),
produced a median PFS of 35.1 months and fewer toxic effects.
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Table 5. Newly diagnosed multiple myeloma: selected clinical trials enrolling transplant-ineligible patients.
Protocol Phase Treatment Subjects Response TTP/PFS/OS Toxicity (≥G3)
NCT00644228
SWOG S0777
[108]
Phase III VRd vs. Rd
VRd 21-day cycles (cycles 1–8)
Bortezomib 1.3 mg/m2 iv D1, 4, 8, and 11 +;
Lenalidomide p.o. 25 mg daily D1–14
Dexamethasone p.o. 20 mg daily D1, 2, 4, 5, 8, 9, 11, and 12
Rd 28-day cycles (cycles 1–6)
Lenalidomide p.o. 25 mg D1–21
Dexamethasone p.o. 40 mg D1, 8, 15, and 22
525
≥VGPR
43% vs. 32%
CR 15.7% vs.
8.4%
Median PFS 43
vs/ 30 months,
median OS 75 vs.
64 months
Neurological
AEs 33% vs. 11%
NCT02195479
ALCYONE [27] Phase III
Dara-VMp vs.
VMp
Induction 42-day cycles
(cycles 1–9)
Bortezomib 1.3 mg/m2 sc twice-weekly on weeks 1, 2, 4,
and 5 of cycle 1 and once weekly on weeks 1, 2, 4, and 5 of
cycles 2–9)
Melphalan p.o. 9 mg/m2 once-daily on D1–4
Prednisone p.o. 60 mg/m2, once-daily on D1–4
Daratumumab iv 16 mg/kg
Dexamethasone 20 mg once-weekly in cycle 1, every 3
weeks in cycles 2–9, and every 4 weeks thereafter until
disease progression
706
≥VGPR 71% vs.
49%
≥CR 42% vs. 24%
MRD neg by
NGS
Dara-VMp arm:
22.3%
VMp arm: 6.2%
Median PFS NR
Neutropenia 40%
vs. 38%
Anemia 16% vs.
19%,
Thrombocytopenia
34% vs. 37%
Pneumonia 11%
vs. 4%
NCT02252172
MAIA [110] Phase III Dara-Rd vs. Rd
Dara–Rd 28-day cycles
Daratumumab iv 16 mg /kg once-weekly during cycles 1–2,
every 2 weeks during cycles 3–6, and every 4 weeks
thereafter
Lenalidomide p.o. 25 mg D1–21
Dexamethasone p.o. 40 mg D1, 8, 15, and 22
Rd 28-day cycle
Lenalidomide p.o. 25 mg D1–21
Dexamethasone p.o. 40 mg D1, 8, 15, and 22
737
≥VGPR 79% vs.
53%
≥CR 47% vs. 24%
MRD neg by
NGS Dara–Rd
arm: 24.2%
Rd arm: 7.3%
Median PFS NR
Neutropenia 50%
vs. 35%
Anemia 12% vs.
20%
Lymphopenia
15% vs. 11%
Pneumonia 14%
vs. 8%
NCT02513186
SARVRD [111] Phase I
Isa-VRd
induction +
Isa-Rd
maintenance (16)
Induction 6-week cycles
Isatuximab iv 10 mg/kg (cycles 1–4)
D1, 8, 15, 22, 29 (cycle 1),; D1, 15, 29 (cycles 2–32 (cycles 1–4)
Lenalidomide p.o. 25 mg/day D1–14 and D22–35 (cycles
1–4)
Dexamethasone 20 mg D1, 2, 4, 5, 8, 9, 11, 12, 15, 22, 23, 25,
26, 29, 30, 32, 33
Maintenance 4-week cycles
Isatuximab iv 10 mg/kg on D1, 15 (all cycles)
Lenalidomide p.o. 25 mg D1–21 (all cycles)
Dexamethasone p.o. 40 mg D1, 8, 15, 22 (all cycles)
22
ORR 93%
MRD neg by
NGS 50% (33% at
10−6)
NGF 44% (18% at
10−6)
NA
G≥3 AEs were
reported in 10
(46%) and SAEs
in 4 (18%) pts
Lymphopenia
(8/22)
Neutropenia
(4/22)
Thrombocytopenia
(4/22)
V, bortezomib; R, lenalidomide; d, dexamethasone; Dara, daratumumab; M, melphalan; p, prednisone; Isa, isatuximab; D, day; iv, intravenous; p.o., orally; sc, subcutaneous; PR, partial
response; VGPR, very good PR; CR, complete response; MRD, minimal residual disease; neg, negative; NGS, next-generation sequencing; NGF, next-generation flow; G, grade; AEs;
adverse events; SAEs, serious AEs.
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Studies exploring the upfront use of anti-CD38 mAbs in transplant-ineligible patients showed deep
responses also in this setting. In the ALCYONE trial, the quadruplet daratumumab–VMP (Dara–VMP)
was compared to VMP showing a clear advantage in PFS (HR 0.50, 95% CI 0.38–0.65, p < 0.001) [27].
At least CR rates were 42 vs. 24% and MRD negativity rates by NGS were 22.3% vs. 6.2%, respectively.
Safety issues mostly consisted of IRRs (overall 27%, grade ≥3 5%) and a high incidence of infections
(grade ≥3 pneumonia 11% vs. 4% in the Dara–VMP vs. VMP arms).
Similarly, in the phase III randomized MAIA study, Dara–Rd significantly prolonged PFS as
compared to Rd (HR 0.56, 95% CI 0.43–0.73, p < 0.001), with ≥CR rates of 47% vs. 24% and MRD
negativity in 24% vs. 7% patients, respectively. The safety profile was similar in the two arms,
but the daratumumab group experienced a higher incidence of neutropenia and infections (including
pneumonia) than the Rd group. As in the ALCYONE study, IRRs were reported in the daratumumab
arm (overall 40%, mostly of grades 1–2 with an incidence of grade ≥3 IRRs of 2.7%) [110].
An ongoing phase I study is investigating isatuximab, in combination with VRd (Isa–VRd): the
first report on 22 patients showed good tolerability, with 46% of grade ≥3 AEs, mostly hematologic.
Besides, response rates are promising, with MRD negativity rates (10−6) by NGS of 33% and by NGF
18% [111].
The good results from the upfront use of second-generation PIs in the transplant-eligible
setting encouraged its exploration in several clinical trials for the treatment of elderly patients.
Carfilzomib associated with melphalan and prednisone (KMP) showed promising results in a phase
I/II study, with 90% ORR and 58% ≥VGPR rates and about 8% of grade ≥3 cardiovascular AEs [112].
However, in the phase III CLARION study, KMP failed to outperform VMP in terms of PFS, OS and
MRD negativity rates [113]. The safety profile was different between the two arms, with KMP inducing
more acute renal failure (any grade 13.9% vs. 6.2%), more cardiac failure (any grade 10.8% vs. 4.3%),
and less peripheral neuropathy (grade ≥2 2.5% vs. 35.1%) than VMP.
The association of carfilzomib with cyclophosphamide dexamethasone (KCd) was evaluated in
two phase I/II studies, the first adopting the once-weekly carfilzomib schedule and the second the
twice-weekly schedule [114,115]. Both trials demonstrated a high efficacy profile (median PFS 35.7
and 35.5 months, respectively; 3-year OS: 72% and 75%) with acceptable toxicity. Overall toxicities
mainly occurred during the induction phase and the incidence of non-hematologic AEs was similar to
that observed with the KMP combination. KCd showed a lower myelotoxicity than KMP and VMP.
Of note, few AEs emerged during maintenance. The once- and twice-weekly schedules were compared
in a meta-analysis, with no significant differences in terms of efficacy and toxicities, and with a benefit
also observed in high-risk patients [116].
5. Future Perspectives
Patient fitness is one of the first factors to consider when planning the treatment strategy. Despite
the manageable profile of some effective combinations, frail patients can unlikely tolerate full-dose
combinations that may induce high MRD negativity. In these patients, disease control rather than cure
may be the more realistically achievable goal. Nevertheless, disease control lasting for a few years,
even without achieving CR or MRD negativity, could allow very elderly patients to have the same
survival of age-matched healthy subjects, considering their actual life expectancy. On the other hand,
in fit patients, the outcome-limiting factor is usually disease progression, and a curative approach
aiming at sustained MRD negativity could be pursued. This approach should incorporate baseline risk
evaluation and dynamic risk evaluation (MRD achievement and duration) during treatment (Figure 1).
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Baseline risk factors such as International Staging System (ISS), cytogenetics, lactate dehydrogenase
(LDH) levels [117], extramedullary disease [118], circulating plasma cells [119], TP53 mutations [94],
and many others can help define our therapeutic strategy. For instance, the use of double ASCT
and long-term treatment with a PI plus IMiDs maintenance could be beneficial in the presence of
high-risk cytogenetics [92]. The dynamic evaluation of patient isk after the start of treatment can
also help tune treatment intensity. Many MRD-driven therapeutic ch ices are under investigation
in clinical trials. One possibility is to evaluate treatment escalation in patients who do not achieve
MRD negativity at a pre-specified time point. In particular, this could be the approach for high-risk
aggressive MM, mirroring a strategy such as the one used for acute leukemia, where achieving MRD is
the goal to achieve cure. Another possibility is to evaluate treatment withholding in patients with
sustained MRD negativity. This could be the option with standard-risk disease, where the disease
behavior is more similar to that of chronic leukemias. In MRD-negative patients, if a reappearance of
MRD is detected, restarting prior therapy if previously interrupted, or starting a different second-line
therapy before the development of an overt relapse, can also be explored. Of note, the deferral of
treatment is currently recommended, even at the reappearance of a monoclonal component (biochemical
relapse), if the increase of the monoclonal component is slow [120]. Treating the reappearance of MRD
might be a further st p for prolonged disease control but its usefulness should be demonstrated in
well-design d trials
Before using MRD i the treatment of MM, several questions need o b answer d. The first
question is in which patients we should test MRD (in CR or sCR patients only, or in VGPR patients).
The rationale to test MRD in VGPR patients is that, due to the long half-life of serum immunoglobulin
(~1 month), the complete clearance of monoclonal component could take months until all the cells
producing it have been eradicated, especially in IgG cases [121]. In these cases, VGPR patients who are
MRD-negative in the bone marrow achieve CR in the months following MRD testing. However, MM is
a spatially heterogeneous disease and residual plasma cells in extramedullary sites can produce the
monoclonal component in VGPR cases in the presence of MRD negativity in the bone marrow. If
this is the case, MRD should probably be measured at sCR and the confirmation of bone marrow
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MRD negativity with imaging techniques should be performed. In the context of a MRD-driven
therapy, it is also tricky to evaluate (a) the impact and the likelihood of “false negative” or “false
positive” MRD results; (b) the right time point; (c) the reasonably achievable cut-off at a specific time
point. For instance, in the transplant-eligible setting, the post-induction time point could be used
to investigate different durations and/or intensifications of induction regimens, and to understand
whether or not intensification with transplant is necessary. It is possible that, after different treatments,
different cut-offs can be achievable. As an example, a 10−5 negativity can be the reasonable goal after
induction, but with prolonged intensification (transplant or further consolidation), a deepest MRD
negativity should likely be the goal. This means that different MRD cut-offs at different time points
should be considered in planning MRD-driven treatment strategies. Moreover, the question is if
treatment decision can rely on a single MRD evaluation, or if, as for all the other response categories,
MRD needs to be confirmed. This also affects the choice of the best time point (for instance, can we
reasonably use a post-induction time point to make decisions on treatment intensification if we consider
an induction with 4 cycles only?). Secondly, we should also consider the importance of MRD duration,
particularly in the context of continuous therapy.
In the transplant-eligible setting, a further issue is the role of checking and the feasibility of pursuing
MRD negativity in the peripheral blood stem-cell collection. Autografts contaminated with MM cells
(MRD-positive autografts at a sensitivity of 10−7 by NGS) predicted a worse PFS than MRD-negative
autografts [122]. However, this effect was mitigated in patients receiving further treatment after ASCT.
Indeed, it should be noted that ASCT, consolidation and maintenance, especially with drugs not used
during induction, still have the potential to eradicate MRD in a substantial number of patients who are
MRD-positive at post-induction time point [7,8,43,70,123].
While the achievement of MRD negativity is clearly predictive of good outcomes, some NDMM
patients are characterized by an MGUS-like plasma cell compartment [124]. In these patients,
long-term disease control can be accomplished without achieving deep responses, probably due
to an immune control of the residual disease. Further research is needed to reliably identify this
patient population.
Moreover, the restoration of a physiological immune system at the time of MRD assessment could
also play a role in predicting the patients that will possibly not relapse [28].
6. Conclusions
In conclusion, we are living exciting times in the field of MM, with many new regimens and
strategies in the pipeline and an increasing knowledge of the complexity of the disease. Even if we
currently do not have any evidence that we are able to cure MM in the great majority of treated patients,
the longer follow-ups of the recent studies will determine the percentage of subjects able to actually
maintain a disease-free status for a very long time. New well-designed MRD-driven trials will help us
determine if it will be worth aiming at the cure of the disease and what will be the best therapeutic
approach to achieve it.
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Abbreviations
IMWG International Myeloma Working Group
MRD minimal residual disease
NGF next-generation flow
NGS next-generation sequencing
FLC free light chain
M-protein myeloma protein
FCM flow cytometry
SUVmax maximum standardized uptake value
MFC multiparameter flow cytometry
FDG Fluorodeoxyglucose
PET/CT Positron emission tomography/computed tomography
N number
TTP time to progression
y year
NR not reached
CA chromosomal abnormalities
PCs plasma cells
BMPCs bone marrow PCs
HR hazard ratio
FLCr free light chain ratio
FISH fluorescence in situ hybridization
Pts patients
V bortezomib
R, Len lenalidomide
d, dex dexamethasone
T thalidomide
FU follow-up
PFS progression-free survival
OS overall survival
G grade
P p-value
MM multiple myeloma
K carfilzomib
CRAB hypercalcemia, renal failure, anemia, and bone lesions
SMM smoldering MM
ORR overall response rate
Dara daratumumab
ASCT autologous stem-cell transplantation
Y years
NA not available
iv intravenous
D day
AE adverse event
sc subcutaneous
p.o. orally
G-CSF granulocyte colony-stimulating factor
Obs. observation
TE Transplant-eligible
NTE non-transplant-eligible
NDMM newly diagnosed multiple myeloma
C cyclophosphamide
PD progressive disease
MR minimal response
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PR partial response
VGPR very good PR
CR complete response
nCR near CR
sCR stringent CR
CHF congestive heart failure
SPMs second primary malignancies
MRD neg MRD negative/negativity
M, Mel melphalan
Mel200 melphalan at 200 mg/m2
Bu busulfan
p prednisone
Ixa ixazomib
SAEs serious AEs
TEAEs treatment-emergent AEs
GIT gastrointestinal toxicity
QW given every week
Q2W given every two weeks
Q4W given every 4 weeks
CI confidence interval
ISS International Staging System
R-ISS Revised ISS
LDH lactate dehydrogenase
EMD extramedullary disease
CPC circulating plasma cells
mAb monoclonal antibody
PI proteasome inhibitor
IMiDs immunomodulatory drugs
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